Why did XAIR stock spike intraday on 13 Jan 2026?

XAIR stock jumped after XTL agreed to buy 85% of Beyond Air’s NeuroNOS subsidiary, including cash, equity and up to $32.50 million in milestones, driving heavy trading and a re-rate of the shares.

What are key valuation metrics for XAIR stock to watch?

Watch EPS **-5.56**, PE **-0.16**, price-to-book **0.44**, current ratio **4.24**, and cash per share **$1.68**. These show liquidity but persistent operating losses for XAIR stock.

What does Meyka AI forecast imply for XAIR stock?

Meyka AI's model projects **$2.33** in five years, implying about **5.02%** upside from **$2.22**. Models also show a lower 1-year projection near **$0.94**. Forecasts are projections, not guarantees.

Is XAIR stock suitable for conservative investors?

No. XAIR stock is event-driven and volatile with negative EPS and small market cap. Conservative investors should avoid or keep very small, risk-managed positions.

US Stocks

XAIR stock Beyond Air (NASDAQ) $2.22 intraday 13 Jan 2026: XTL deal lifts volume

ByHuzaifa Zahoor January 14, 2026January 14, 2026

XAIR stock is trading at $2.22 intraday on 13 Jan 2026 after news that XTL Biopharmaceuticals agreed to acquire 85% of Beyond Air’s NeuroNOS subsidiary. The move lifted shares from a previous close of $0.88 to a day high of $2.66 on heavy activity. Volume is extraordinary at 376,345,293.00 shares versus an average of 491,677.00, and traders are pricing the deal impact into NASDAQ-listed Beyond Air, Inc. (United States, USD). We review the catalyst, technicals, valuation and Meyka AI’s forecast for XAIR stock